Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.

And the deals it has signed recently will not begin to pay off for some years to come.